Medarex

Overview

Medarex is a biotechnology company headquartered in Princeton, United States, founded in 1987, with 201-500 employees.

API / Drug Master Files

Medarex holds 0 active (8 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• MDX-1303 VALORTIM (TM), ANTI-BACILLUS ANTHRACIS PROTECTIVE ANTIGEN HUMAN MONOCLONAL ANTIBODYInactive2005-06-24
• HUMAN MONOCLONAL ANTIBODY (MDX-067) TO HEPARANASEInactive2003-09-22
• HUMAN MONOCLONAL ANTIBODY (MDX-214) TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)Inactive2003-06-24
• MDX-015 (ANTI-IL15 HUMAN MONOCLONAL ANTIBODY)Inactive2003-03-18
• HUMAN MONOCLONAL ANTIBODY (MDX-070) TO PROSTATE SPECIFIC MEMBRANE ANTIGENInactive2002-12-09
• MURINE MONOCLONAL ANTIBODY (ALPHA CTLA4) TOCTLA4Inactive1999-10-06
• RICIN CONJUGATED MURINE MONOCLONAL ANTIBODY (MDX-RA) TO HUMAN LENS EPITHELIAL CELLSInactive1997-11-12
• MURINE MONOCLONAL ANTIBODY (PM-81) TO HUMAN MYELOID DIFFERENTIATION ANTIGENInactive1991-08-01

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Medarex in our records. PharmaTek screens the full directory against live FDA enforcement data.